Practical introduction of novel oral anticoagulants through an anticoagulation nurse. The Leeuwarden model

被引:2
|
作者
Folkeringa, R. J. [1 ]
Geven, L. M. [2 ]
Veldhuis, T. [2 ]
Hoogendoorn, M. [3 ]
Hofma, S. H. [1 ]
Van Roon, E. [4 ]
机构
[1] Med Ctr Leeuwarden, Dept Cardiol, NL-8934 AD Leeuwarden, Netherlands
[2] Thrombosis Serv Friesland Noord, NL-8934 AD Leeuwarden, Netherlands
[3] Med Ctr Leeuwarden, Dept Internal Med, NL-8934 AD Leeuwarden, Netherlands
[4] Med Ctr Leeuwarden, Dept Pharm, NL-8934 AD Leeuwarden, Netherlands
关键词
Atrial fibrillation; Novel oral anticoagulants; Anticoagulation; ATRIAL-FIBRILLATION; GUIDELINES; MANAGEMENT;
D O I
10.1007/s12471-014-0529-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction This paper describes the implementation of novel oral anticoagulants (NOACs) through an anticoagulation nurse. Logistics and tasks of this new function are described and preliminary data are presented. Methods Indications for NOACs are explained by the treating cardiologists. Thereafter, the patient is referred to the anticoagulation nurse before starting a NOAC. After providing a patient with information and checking the creatinine clearance, co-medication and medical history, a prescription for NOAC is made. Results In 3 months, 51 patients were referred for NOAC therapy. Mean age was 68 years, CHA2DS2-VASc score was 2.9. Renal function was impaired in 28 %. Only 63 % of the patients had an uneventful start-up. NOAC therapy was withheld or prematurely stopped in 22 %. 30 % of patients needed a reduced NOAC dose. In 37 %, the anticoagulation nurse had extended patient contact, mainly because of (presumed) side effects. Conclusion Given the number of interactions that were made using a separate patient contact through the anticoagulation nurse, this seems to be an important improvement in the quality of care and deserves further expansion.
引用
收藏
页码:297 / 300
页数:4
相关论文
共 50 条
  • [41] The Introduction of Novel Oral Anticoagulants (NOAC): our Experience of Implementing their Use on the Acute Stroke Unit and Stroke Prevention Clinic
    Gill, S. K.
    Collas, D. M.
    CEREBROVASCULAR DISEASES, 2014, 37 : 525 - 525
  • [42] Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction
    Simon Schwill
    Katja Krug
    Frank Peters-Klimm
    Jan van Lieshout
    Gunter Laux
    Joachim Szecsenyi
    Michel Wensing
    BMC Family Practice, 19
  • [43] Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016
    Maura, Geric
    Billionnet, Cecile
    Drouin, Jerome
    Weill, Alain
    Neumann, Anke
    Pariente, Antoine
    BMJ OPEN, 2019, 9 (04):
  • [44] DEVELOPMENT OF AN INSTITUTIONAL COST OF CARE MODEL FOR ANTICOAGULATION MANAGEMENT OF PATIENTS WITH WARFARIN VERSUS NOVEL ORAL AGENTS
    Pizzi, L. T.
    Thomson, L.
    Jutkowitz, E.
    Vogenberg, F. R.
    Swift, B.
    Merli, G.
    VALUE IN HEALTH, 2011, 14 (07) : A380 - A380
  • [45] Would you use novel oral anticoagulants (NOACs) for thromboprophylaxis in patients with an underlying hypercoagulable state? A literature review through a case report
    Kakadia, Bhavika
    Suero-Abreu, Giselle Alexandra
    Daci, Rrita
    Then, Ryna Karina
    BMJ CASE REPORTS, 2020, 13 (10)
  • [46] A NOVEL APPROACH TO ESTIMATING THE RISK OF HARM DUE TO DRUG-DRUG INTERACTIONS: AN EXEMPLARY MODEL WITH COMMON MEDIATIONS THAT INTERACT WITH ORAL ANTICOAGULANTS
    Gomez-Lumbreras, A.
    Tawfik, A. G.
    Malone, D.
    VALUE IN HEALTH, 2024, 27 (06) : S24 - S25
  • [47] NATIONWIDE EXTRAPOLATION OF ECONOMIC IMPACT OF THERAPEUTIC INNOVATION: A 10-YEAR RETROSPECTIVE BUDGET IMPACT MODEL OF DIRECT ORAL ANTICOAGULANTS (DOAC) INTRODUCTION IN FRANCE
    Guilmet, C.
    Moreau, R.
    Cotte, F. E.
    Lesage, H.
    Marant, Micallef C.
    Nee, M.
    Guitard-Dehoux, D.
    Belhassen, M.
    Danchin, N.
    VALUE IN HEALTH, 2024, 27 (12) : S94 - S94
  • [48] TRIPLE THERAPY ANTICOAGULATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) WITH NOVEL ORAL ANTICOAGULANTS (NOAC) IS SAFE AND HAS NO ADVERSE EFFECTS ON BLEEDING POST PROCEDURE WHEN COMPARED TO TRIPLE THERAPY WITH VITAMIN K ANTAGONIST (VKA)
    Amin, Reshma
    McWilliams, Nicholas
    Lee, Deacon
    Altaf, Fatima
    Virani, Farzana
    Dickinson, Katherine
    Walker, David
    Sharp, Andrew
    Gerber, Robert
    HEART, 2016, 102 : A25 - A25
  • [49] BASELINE CLINICAL AND DEMOGRAPHIC DIFFERENCES OFAF-PATIENTS UNDER DIFFERENT ANTICOAGULATION SCHEMES PRESTROKE: FIRST RESULTS FROM THE REGISTRY OF ACUTE STROKE UNDER NOVEL ORAL ANTICOAGULANTS-PRIME (RASUNOA-PRIME)
    Haas, K.
    Purrucker, J.
    Fiessler, C.
    Rizos, T.
    Heuschmann, P.
    Veltkamp, R.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 66 - 67
  • [50] Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?
    Goto, Shinichi
    Goto, Shinya
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2015, 1 (02) : 83 - 85